Developer docs
API playgroundTry for free, no card

Search company profiles

Remix Therapeutics

Full company profile

uuid0000odr

Namestring
Remix Therapeutics
Legal namestring
Remix Therapeutics, Inc.
Websiteurl
remixtx.com
Company typeenum
Private
Founded yearint
2020
Descriptiontext

Remix Therapeutics is a clinical-stage biotechnology company founded in 2020 and headquartered in Watertown, Massachusetts, that develops small molecule therapeutics designed to modulate RNA processing and thereby control the expression of disease-driving genes and proteins. Its scientific platform, REMaster, integrates machine learning algorithms with a proprietary transcriptome database (reported to cover more than 1.6 million novel exon targets, ~25x the largest public database), multiplexed high-throughput cell-based and cell-free screening, and a purpose-built RNA-targeted chemical library. The platform's lead clinical output is REM-422, a first-in-class, orally bioavailable small molecule mRNA degrader that induces poison exon inclusion in MYB mRNA, triggering nonsense-mediated decay and reducing MYB protein levels — a mechanism directed at a transcription factor historically considered undruggable.

REM-422 is currently in a Phase 1/2 study (ARIA) for recurrent/metastatic adenoid cystic carcinoma (ACC) and a Phase 1 study in acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome, conducted across eight US academic cancer centers. Interim data disclosed in 2026 reported a 43% overall response rate and 100% disease control rate at the recommended Phase 2 dose in ACC. The candidate has received FDA Orphan Drug Designation in ACC and AML and FDA Fast Track Designation in recurrent/metastatic ACC. Remix's pipeline also targets additional oncology indications and neurodegenerative diseases.

Remix is pre-revenue and generates cash through strategic R&D collaborations and equity financing rather than product sales. It received $45M upfront from Janssen (Johnson & Johnson) in 2022 and $30M upfront from Roche in 2024, each with potential milestone payments exceeding $1 billion plus tiered royalties, plus equity rounds totaling roughly $211M (including a $60M round in January 2024 led by The Column Group) and a $100M PIPE in June 2026 led by Decheng Capital concurrent with its announced reverse merger with Passage Bio (Nasdaq listing as RMTX expected Q4 2026, with pre-merger Remix holders owning ~93%).

Short descriptiontext

Remix Therapeutics is a clinical-stage Watertown, MA biotech developing small molecule drugs that modulate RNA processing via its REMaster platform, with lead candidate REM-422 (an oral MYB mRNA degrader) in Phase 1/2 trials for adenoid cystic carcinoma and AML.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersWatertown, United States
HQ citystring
Watertown
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices9 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
RNA processing therapeutics, small molecule discovery, mRNA degrader technology, oncology drug development, clinical stage biotechnology
Industry1 code
PRIMARYHLAAADAA
mRNA Therapeutics (vaccines, protein replacement, immuno-oncology)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
RNA-Targeted Therapeutics
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Pharmaceutical R&D/Partnership Revenues
TypeLicensing Royalties
Description

Pre-revenue clinical-stage biotech company. Generates income through strategic partnerships with pharmaceutical companies including upfront payments, milestone payments, and royalty payments on potential commercial products. Received $45M upfront from Janssen collaboration (2022) and $30M upfront from Roche collaboration (2024).

remixtx.com
2Future Product Sales
TypeOne Time License
Description

Potential future revenue from commercialization of lead candidate REM-422 and other pipeline programs in oncology and neurodegeneration. REM-422 is currently in Phase 1/2 clinical trials for ACC and AML.

remixtx.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Remix Therapeutics is a clinical-stage biotechnology company that develops small molecule therapeutics designed to modulate RNA processing and control gene expression. Its proprietary REMaster™ drug discovery platform uses machine learning, proprietary transcriptomic data, and high-throughput multiplexed screening to identify chemical matter against historically undruggable targets, with lead candidate REM-422, a first-in-class oral mRNA degrader targeting MYB, currently in Phase 1/2 clinical trials for adenoid cystic carcinoma and acute myeloid leukemia.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 43% overall response rate and 100% disease control rate in recurrent/metastatic ACC patients at recommended Phase 2 dose
+2 more records
Product overview1 text field

Remix Therapeutics is advancing a new class of small molecule therapeutics designed to reprogram RNA processing. The company's core offering consists of the proprietary REMaster™ Drug Discovery Platform, which leverages machine learning, transcriptomic data, and high-throughput screening to identify compounds that modulate gene expression at the RNA level. The lead clinical candidate is REM-422, a first-in-class oral mRNA degrader targeting the MYB transcription factor, currently in Phase 1/2 trials for adenoid cystic carcinoma and Phase 1 for acute myeloid leukemia. The platform and pipeline address previously undruggable disease drivers in oncology and neurodegeneration.

Product and service2 records
1REMaster™ Drug Discovery Platform
CategoryDrug Discovery Platform
Description

Proprietary drug discovery platform that identifies druggable RNA processing target sites and active chemical matter using machine learning algorithms, extensive transcriptomic datasets, multiplexed high-throughput cell-based and cell-free screening assays, and a proprietary RNA-targeted small molecule library, enabling modulation of gene expression for historically undruggable disease drivers.

2REM-422
CategoryInvestigational Therapeutic (Lead Clinical Asset)
Description

First-in-class orally available small molecule mRNA degrader that targets the MYB transcription factor by inducing poison exon incorporation in MYB mRNA, leading to nonsense-mediated decay of the transcript and reduction of MYB protein expression. Currently in Phase 1/2 clinical trials for adenoid cystic carcinoma (ACC) and Phase 1 for acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS); has received FDA Orphan Drug Designation for ACC and AML and FDA Fast Track designation for recurrent, metastatic or unresectable ACC.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-06-24
Description

All-stock reverse merger agreement. Pre-merger Remix stockholders will own approximately 93% of combined company. Combined entity will operate as Remix Therapeutics and trade on Nasdaq under ticker RMTX. Expected to close Q4 2026.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-01-03
Description

Collaboration and license agreement for discovery and development of small molecule therapeutics modulating RNA processing using Remix's REMaster platform. Remix received $30M upfront and up to $12M in near-term milestones, with potential total payments up to $1 billion plus tiered royalties. Roche receives exclusive rights to specific targets and is responsible for development and commercialization.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2022-02-17
Description

Multi-year, three target strategic collaboration for discovery and development of small molecule therapeutics modulating RNA processing in oncology and immunology. Remix received $45M upfront and may receive total payments potentially exceeding $1 billion including preclinical, clinical, commercial, sales milestones and tiered royalties. Remix has option to opt into one program's clinical development costs for higher royalties.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

ProQR Therapeutics develops RNA-targeted therapeutics, including Axiomer RNA editing technology. It is a broad peer in the RNA therapeutics space with a different delivery modality but comparable focus on modulating RNA to treat genetic disease.

TypeEmerging player
Description

Stoke Therapeutics develops antisense oligonucleotide medicines that increase protein production by modulating RNA splicing. It is an emerging peer in the RNA-targeted therapeutics space, with a different modality (ASO) than Remix's small molecules.

TypeDirect peer
Description

Accent Therapeutics develops small molecule therapies that target RNA-modifying proteins, with a focus on oncology. It is comparable to Remix in the precision oncology / RNA biology space, though the molecular target class differs.

TypeBroad incumbent
Description

Arvinas is a clinical-stage leader in targeted protein degradation (PROTAC). While it degrades proteins rather than mRNA, it pioneered the small molecule degrader modality and serves as the closest analog for Remix's mRNA degrader approach at scale.

TypeDirect peer
Description

Kymera Therapeutics is a clinical-stage biotech developing small molecule targeted protein degraders using its Pegasus platform. It is comparable to Remix as a degrader-focused small molecule company pursuing historically undruggable oncology targets.

TypeDirect peer
Description

Foghorn Therapeutics develops small molecule drugs that target chromatin regulatory systems to modulate gene expression. It is directly comparable to Remix as a clinical-stage precision oncology company that targets gene expression regulation.

7Expansion Therapeutics
TypeDirect peer
Description

Expansion Therapeutics develops small molecule RNA-targeting drugs, with a focus on repeat expansion diseases. It is a direct platform peer, leveraging small molecules to modulate RNA processing for therapeutic benefit.

TypeDirect peer
Description

Arrakis Therapeutics designs small molecule drugs that bind RNA structures, including mRNA. It pursues a directly comparable approach to Remix, with platform-based RNA targeting and oncology/pipeline focus, supported by partnerships with large pharma.

TypeDirect peer
Description

Skyhawk Therapeutics develops small molecules that target RNA, including RNA splicing modulators. It is the closest direct competitor to Remix in the RNA-targeted small molecule space, with a similar platform-plus-pipeline model and major pharma partnerships.

10Syros Pharmaceuticals
TypeBroad incumbent
Description

Syros Pharmaceuticals pioneered small molecule gene expression control therapeutics. It is a broad peer to Remix in the gene regulation / transcription control space, with a longer operating history in clinical development.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors9 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Remix Therapeutics

RNA-Targeted Therapeuticsremixtx.com

Remix Therapeutics is a clinical-stage Watertown, MA biotech developing small molecule drugs that modulate RNA processing via its REMaster platform, with lead candidate REM-422 (an oral MYB mRNA degrader) in Phase 1/2 trials for adenoid cystic carcinoma and AML.

What Remix Therapeutics does

Remix Therapeutics is a clinical-stage biotechnology company founded in 2020 and headquartered in Watertown, Massachusetts, that develops small molecule therapeutics designed to modulate RNA processing and thereby control the expression of disease-driving genes and proteins. Its scientific platform, REMaster, integrates machine learning algorithms with a proprietary transcriptome database (reported to cover more than 1.6 million novel exon targets, ~25x the largest public database), multiplexed high-throughput cell-based and cell-free screening, and a purpose-built RNA-targeted chemical library. The platform's lead clinical output is REM-422, a first-in-class, orally bioavailable small molecule mRNA degrader that induces poison exon inclusion in MYB mRNA, triggering nonsense-mediated decay and reducing MYB protein levels — a mechanism directed at a transcription factor historically considered undruggable.

REM-422 is currently in a Phase 1/2 study (ARIA) for recurrent/metastatic adenoid cystic carcinoma (ACC) and a Phase 1 study in acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome, conducted across eight US academic cancer centers. Interim data disclosed in 2026 reported a 43% overall response rate and 100% disease control rate at the recommended Phase 2 dose in ACC. The candidate has received FDA Orphan Drug Designation in ACC and AML and FDA Fast Track Designation in recurrent/metastatic ACC. Remix's pipeline also targets additional oncology indications and neurodegenerative diseases.

Remix is pre-revenue and generates cash through strategic R&D collaborations and equity financing rather than product sales. It received $45M upfront from Janssen (Johnson & Johnson) in 2022 and $30M upfront from Roche in 2024, each with potential milestone payments exceeding $1 billion plus tiered royalties, plus equity rounds totaling roughly $211M (including a $60M round in January 2024 led by The Column Group) and a $100M PIPE in June 2026 led by Decheng Capital concurrent with its announced reverse merger with Passage Bio (Nasdaq listing as RMTX expected Q4 2026, with pre-merger Remix holders owning ~93%).

Remix Therapeutics firmographics

Firmographics
Name
Remix Therapeutics
Legal name
Remix Therapeutics, Inc.
Website
https://remixtx.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
51–100 employees
Short description
Remix Therapeutics is a clinical-stage Watertown, MA biotech developing small molecule drugs that modulate RNA processing via its REMaster platform, with lead candidate REM-422 (an oral MYB mRNA degrader) in Phase 1/2 trials for adenoid cystic carcinoma and AML.
Ownership category
akta.pro rank

Remix Therapeutics industry classification

Industry
Product category
RNA-Targeted Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAADAA
mRNA Therapeutics (vaccines, protein replacement, immuno-oncology)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)

Keywords

  • RNA processing therapeutics
  • Small molecule discovery
  • MRNA degrader technology
  • Oncology drug development
  • Clinical stage biotechnology

Where Remix Therapeutics is headquartered

Location

Headquarters

HQ city
Watertown
HQ country
United States
HQ region
North America

Offices9 records

Markets served

Remix Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Pharmaceutical R&D/Partnership Revenues: Pre-revenue clinical-stage biotech company. Generates income through strategic partnerships with pharmaceutical companies including upfront payments, milestone payments, and royalty payments on potential commercial products. Received $45M upfront from Janssen collaboration (2022) and $30M upfront from Roche collaboration (2024).
  2. Future Product Sales: Potential future revenue from commercialization of lead candidate REM-422 and other pipeline programs in oncology and neurodegeneration. REM-422 is currently in Phase 1/2 clinical trials for ACC and AML.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Remix Therapeutics product offering

Product offering

Core offering

Remix Therapeutics is a clinical-stage biotechnology company that develops small molecule therapeutics designed to modulate RNA processing and control gene expression. Its proprietary REMaster™ drug discovery platform uses machine learning, proprietary transcriptomic data, and high-throughput multiplexed screening to identify chemical matter against historically undruggable targets, with lead candidate REM-422, a first-in-class oral mRNA degrader targeting MYB, currently in Phase 1/2 clinical trials for adenoid cystic carcinoma and acute myeloid leukemia.

Product overview

Remix Therapeutics is advancing a new class of small molecule therapeutics designed to reprogram RNA processing. The company's core offering consists of the proprietary REMaster™ Drug Discovery Platform, which leverages machine learning, transcriptomic data, and high-throughput screening to identify compounds that modulate gene expression at the RNA level. The lead clinical candidate is REM-422, a first-in-class oral mRNA degrader targeting the MYB transcription factor, currently in Phase 1/2 trials for adenoid cystic carcinoma and Phase 1 for acute myeloid leukemia. The platform and pipeline address previously undruggable disease drivers in oncology and neurodegeneration.

Differentiator

Problem solved

Functional benefit

Products and services

  • REMaster™ Drug Discovery Platform Proprietary drug discovery platform that identifies druggable RNA processing target sites and active chemical matter using machine learning algorithms, extensive transcriptomic datasets, multiplexed high-throughput cell-based and cell-free screening assays, and a proprietary RNA-targeted small molecule library, enabling modulation of gene expression for historically undruggable disease drivers.
  • REM-422 First-in-class orally available small molecule mRNA degrader that targets the MYB transcription factor by inducing poison exon incorporation in MYB mRNA, leading to nonsense-mediated decay of the transcript and reduction of MYB protein expression. Currently in Phase 1/2 clinical trials for adenoid cystic carcinoma (ACC) and Phase 1 for acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS); has received FDA Orphan Drug Designation for ACC and AML and FDA Fast Track designation for recurrent, metastatic or unresectable ACC.

Quantifiable outcome

  • 43% overall response rate and 100% disease control rate in recurrent/metastatic ACC patients at recommended Phase 2 dose
  • +2 more outcomes

Companies that use Remix Therapeutics

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Remix Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Remix Therapeutics partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered flagship and core.

  • Passage BioflagshipStrategic or Co-development Partner · 24 June 2026All-stock reverse merger agreement. Pre-merger Remix stockholders will own approximately 93% of combined company. Combined entity will operate as Remix Therapeutics and trade on Nasdaq under ticker RMTX. Expected to close Q4 2026.
  • RochecoreStrategic or Co-development Partner · 3 January 2024Collaboration and license agreement for discovery and development of small molecule therapeutics modulating RNA processing using Remix's REMaster platform. Remix received $30M upfront and up to $12M in near-term milestones, with potential total payments up to $1 billion plus tiered royalties. Roche receives exclusive rights to specific targets and is responsible for development and commercialization.
  • Janssen Pharmaceutica NV (Johnson & Johnson)flagshipStrategic or Co-development Partner · 17 February 2022Multi-year, three target strategic collaboration for discovery and development of small molecule therapeutics modulating RNA processing in oncology and immunology. Remix received $45M upfront and may receive total payments potentially exceeding $1 billion including preclinical, clinical, commercial, sales milestones and tiered royalties. Remix has option to opt into one program's clinical development costs for higher royalties.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Remix Therapeutics competitors and assessment

Company assessment

Broad incumbents

  • ProQR Therapeutics: ProQR Therapeutics develops RNA-targeted therapeutics, including Axiomer RNA editing technology. It is a broad peer in the RNA therapeutics space with a different delivery modality but comparable focus on modulating RNA to treat genetic disease.
  • Arvinas: Arvinas is a clinical-stage leader in targeted protein degradation (PROTAC). While it degrades proteins rather than mRNA, it pioneered the small molecule degrader modality and serves as the closest analog for Remix's mRNA degrader approach at scale.
  • Syros Pharmaceuticals: Syros Pharmaceuticals pioneered small molecule gene expression control therapeutics. It is a broad peer to Remix in the gene regulation / transcription control space, with a longer operating history in clinical development.

Emerging players

  • Stoke Therapeutics: Stoke Therapeutics develops antisense oligonucleotide medicines that increase protein production by modulating RNA splicing. It is an emerging peer in the RNA-targeted therapeutics space, with a different modality (ASO) than Remix's small molecules.

Direct peers

  • Accent Therapeutics: Accent Therapeutics develops small molecule therapies that target RNA-modifying proteins, with a focus on oncology. It is comparable to Remix in the precision oncology / RNA biology space, though the molecular target class differs.
  • Kymera Therapeutics: Kymera Therapeutics is a clinical-stage biotech developing small molecule targeted protein degraders using its Pegasus platform. It is comparable to Remix as a degrader-focused small molecule company pursuing historically undruggable oncology targets.
  • Foghorn Therapeutics: Foghorn Therapeutics develops small molecule drugs that target chromatin regulatory systems to modulate gene expression. It is directly comparable to Remix as a clinical-stage precision oncology company that targets gene expression regulation.
  • Expansion Therapeutics: Expansion Therapeutics develops small molecule RNA-targeting drugs, with a focus on repeat expansion diseases. It is a direct platform peer, leveraging small molecules to modulate RNA processing for therapeutic benefit.
  • Arrakis Therapeutics: Arrakis Therapeutics designs small molecule drugs that bind RNA structures, including mRNA. It pursues a directly comparable approach to Remix, with platform-based RNA targeting and oncology/pipeline focus, supported by partnerships with large pharma.
  • Skyhawk Therapeutics: Skyhawk Therapeutics develops small molecules that target RNA, including RNA splicing modulators. It is the closest direct competitor to Remix in the RNA-targeted small molecule space, with a similar platform-plus-pipeline model and major pharma partnerships.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Remix Therapeutics social profiles

Digital presence

Remix Therapeutics compliance and trust

Trust signal

Compliance2 records

Remix Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Remix Therapeutics leadership team

Management profile

Number of profiles

Profiles7 records

Remix Therapeutics funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Remix Therapeutics M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Remix Therapeutics

What does Remix Therapeutics do?

Remix Therapeutics is a clinical-stage biotechnology company that develops small molecule therapeutics designed to modulate RNA processing and control gene expression. Its proprietary REMaster™ drug discovery platform uses machine learning, proprietary transcriptomic data, and high-throughput multiplexed screening to identify chemical matter against historically undruggable targets, with lead candidate REM-422, a first-in-class oral mRNA degrader targeting MYB, currently in Phase 1/2 clinical trials for adenoid cystic carcinoma and acute myeloid leukemia.

Is Remix Therapeutics a public or private company?

Remix Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Remix Therapeutics founded?

Remix Therapeutics was founded in 2020. It employs 51 to 100 people.

Where is Remix Therapeutics based?

Remix Therapeutics is headquartered in Watertown, United States, in the North America region.

How does Remix Therapeutics make money?

Two revenue lines are on record. Pharmaceutical R&D/Partnership Revenues are the primary driver. The others are future Product Sales.

Who are Remix Therapeutics's main competitors?

Broad incumbents on record are ProQR Therapeutics, Arvinas and Syros Pharmaceuticals. Stoke Therapeutics is listed as an emerging player. Direct peers are Accent Therapeutics, Kymera Therapeutics, Foghorn Therapeutics, Expansion Therapeutics, Arrakis Therapeutics and Skyhawk Therapeutics.

Does Remix Therapeutics have an API?

No public API is recorded for Remix Therapeutics.

What industry is Remix Therapeutics in?

Remix Therapeutics's product category is RNA-Targeted Therapeutics. Its primary akta.pro industry code is HLAAADAA, mRNA Therapeutics (vaccines, protein replacement, immuno-oncology). Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business & FinancialRemix Therapeutics Selected For Late-Breaking Oral Presentation At The 38Th EORTC-NCI-AACR SymposiumRemix Therapeutics will present updated interim results from the Phase 1/2 ARIA study of its MYB mRNA degrader REM-422 in Adenoid Cystic Carcinoma at the 38th EORTC-NCI-AACR Symposium in Barcelona. The presentation highlights durable responses and prolonged progression-free survival, with no FDA-approved systemic therapies for ACC.AD HOC NEWSPassage Bio ändert Fusionsplan: Was das für die Passage-Bio-Aktie bedeutetPassage Bio amended its merger plan with Remix Therapeutics, setting a shareholder vote for November 5, 2026. The deal requires $99.929 million in financing, with existing Passage Bio shareholders retaining 6% and Remix shareholders 65%. The combined company will be named Remix Therapeutics, listed on Nasdaq under RMTX.FinancialContent Business PageRemix Therapeutics™ Appoints Michael Landsittel to Board of DirectorsRemix Therapeutics appointed Michael Landsittel to its Board of Directors. Landsittel previously served as CFO at Blueprint Medicines, guiding its $9.1 billion acquisition by Sanofi in 2025. He will support Remix's RNA processing platform and public company operations.FinancialContent Business PageRemix Therapeutics to Present at 46th Annual Canaccord Genuity Growth ConferenceRemix Therapeutics announced that CEO Peter Smith will present a corporate overview at the 46th Annual Canaccord Genuity Growth Conference on August 11, 2026, in Boston. The event aims to facilitate one-on-one meetings between the Remix management team and investors. This presentation signifies Remix's efforts to engage with potential investors and raise awareness about its RNA processing therapies.GlobeNewswireRemix Therapeutics to Present at 46th Annual Canaccord Genuity Growth ConferenceRemix Therapeutics announced that its Co-Founder and CEO will present at the 46th Annual Canaccord Genuity Growth Conference on August 11, 2026, in Boston, with the management team also hosting one-on-one investor meetings. The clinical-stage biotechnology company is developing small molecule RNA processing modulators, with its lead candidate REM-422 currently in Phase 1/2 trials for acute myeloid leukemia and Phase 1 trials for myelodysplastic syndrome and adenoid cystic carcinoma. The announcement is a routine investor relations activity with no new clinical data or strategic developments disclosed.FinancialContent Business PageRemix Therapeutics to Present at AACR Drug Discovery and Development ConferenceRemix Therapeutics announced that its Co-Founder and CEO will present at the AACR Drug Discovery and Development Conference in Boston on July 24, 2026, providing an update on the ongoing Phase 1/2 ARIA study of its lead candidate REM-422. The company reported clinical activity, durability of response, and favorable safety results to date from the trial targeting MYB-driven cancers, including adenoid cystic carcinoma. REM-422 has received Orphan Drug Designation for adenoid cystic carcinoma and acute myeloid leukemia, as well as Fast Track designation for ACC, from the U.S. Food and Drug Administration.GlobeNewswireRemix Therapeutics to Present at AACR Drug Discovery andRemix Therapeutics announced that its Co-Founder and CEO will present at the AACR Drug Discovery and Development Conference in Boston on July 24, 2026, providing a corporate update on their ongoing Phase 1/2 ARIA study of REM-422. The presentation will highlight clinical activity, durability of response, and favorable safety results observed to date for REM-422, their oral small molecule mRNA degrader targeting MYB-driven cancers including adenoid cystic carcinoma. The company noted that their RNA processing approach may offer a new therapeutic option for patients with limited treatment alternatives, as there are currently no approved treatments for ACC.BioSpaceRemix Therapeutics to Present at AACR Drug Discovery and Development ConferenceRemix Therapeutics CEO Peter Smith will present at the AACR Drug Discovery and Development Conference in Boston on July 24, 2026, highlighting Phase 1 data for REM-422 in adenoid cystic carcinoma. The data show a 43% overall response rate and durable responses exceeding one year with favorable safety results.American City Business JournalsRemix Therapeutics secures $100M, merges with PassageRemix Therapeutics will merge with Passage Bio and go public under the ticker RMTX. The company secured $100 million in private placement financing from Decheng Capital and others. The combined firm has cash to fund operations through 2028.LwLatham & Watkins Advises Remix Therapeutics in Merger With Passage BioPassage Bio and Remix Therapeutics have entered into a definitive merger agreement to combine in an all-stock transaction, with the combined entity operating under the name Remix Therapeutics. Latham & Watkins LLP is advising Remix Therapeutics on this corporate transaction.